About
In the 1970s, Levodopa was the first drug approved specifically
for Parkinson's. Levodopa is converted by enzymes in the brain
to produce dopamine, thereby supplementing function that has
been lost as dopamine-producing neurons die.
Levodopa is most frequently combined with Carbidopa to slow
enzyme break down of Levodopa before it reaches the brain. In
the United States, this Levodopa/ Carbidopa combination may be
sold under the brand name Sinemet.
Sinemet is available in both standard release and controlled
release preparations.
|
Pros
In most patients, Levodopa/Carbidopa significantly improves
mobility and allows them to function relatively normally, at
least in the early stages of the disease. Because Parkinson's
worsens over time, increased doses must be taken to manage
symptoms as they progress.
Levodopa/Carbidopa is widely recognized as the most effective
treatment for motor symptoms of the disease.
|
Cons and Complications
Levodopa/Carbidopa has not been shown to slow disease
progression. Additionally, the drug has significant side effects
for some patients, including dyskinesia (involuntary movements
and tics), hallucinations and illusions.
Over time, symptoms may begin to come back before it is time for
another dose of Levodopa/Carbidopa. This change in symptoms is
called "wearing-off."
As "wearing-off" becomes more noticeable, the duration of good
response to Levodopa/Carbidopa (known as "on" time) shortens,
while the duration of poor response (known as "off" time) may
lengthen.
High protein-diets may inhibit Levodopa/Carbidopa absorption in
some people, thus impacting drug effectiveness.
Not effective at treating all symptoms of PD. Posture,
depression and cognitive problems are not responsive to
Levodopa-Carbidopa.
|